LENSAR Q3 net loss widens

Reuters11-06

LENSAR Q3 net loss widens

Overview

LENSAR Q3 2025 revenue rises 6% yr/yr, driven by increased procedure volume
Net loss widens to $3.7 mln in Q3, impacted by acquisition-related costs
ALLY installed base grows 77% yr/yr, reflecting strong market adoption

Outlook

Company expects Alcon acquisition to close in Q1 2026

Result Drivers

ALLY ADOPTION - Significant growth in ALLY installed base, increasing by 77% yr/yr, driving revenue growth
PROCEDURE VOLUME - Worldwide procedure volume increased by 11% in Q3 2025, contributing to revenue growth
ACQUISITION COSTS - Net loss impacted by $5.3 mln in costs related to pending Alcon acquisition

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$3.70 mln
Q3 EBITDA		-$2.70 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for LENSAR Inc is $15.00, about 16.5% above its November 5 closing price of $12.52

Press Release: ID:nGNX1j5kbj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581346060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581346060","market":"fut","top_or_hot":-1,"title":"LENSAR Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>LENSAR Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>LENSAR Q3 2025 revenue rises 6% yr/yr, driven by increased procedure volume</p></li><li><p>Net loss widens to $3.7 mln in Q3, impacted by acquisition-related costs</p></li><li><p>ALLY installed base grows 77% yr/yr, reflecting strong market adoption</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects Alcon acquisition to close in Q1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ALLY ADOPTION - Significant growth in ALLY installed base, increasing by 77% yr/yr, driving revenue growth</p></li><li><p>PROCEDURE VOLUME - Worldwide procedure volume increased by 11% in Q3 2025, contributing to revenue growth</p></li><li><p>ACQUISITION COSTS - Net loss impacted by $5.3 mln in costs related to pending Alcon acquisition</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.70 mln</p></td><td></td></tr><tr><td><p>Q3 EBITDA</p></td><td></td><td><p>-$2.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/LNSR\">LENSAR Inc</a> is $15.00, about 16.5% above its November 5 closing price of $12.52</p></li></ul><p>Press Release: <span>ID:nGNX1j5kbj</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LENSAR Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLENSAR Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>LENSAR Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>LENSAR Q3 2025 revenue rises 6% yr/yr, driven by increased procedure volume</p></li><li><p>Net loss widens to $3.7 mln in Q3, impacted by acquisition-related costs</p></li><li><p>ALLY installed base grows 77% yr/yr, reflecting strong market adoption</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects Alcon acquisition to close in Q1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ALLY ADOPTION - Significant growth in ALLY installed base, increasing by 77% yr/yr, driving revenue growth</p></li><li><p>PROCEDURE VOLUME - Worldwide procedure volume increased by 11% in Q3 2025, contributing to revenue growth</p></li><li><p>ACQUISITION COSTS - Net loss impacted by $5.3 mln in costs related to pending Alcon acquisition</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.70 mln</p></td><td></td></tr><tr><td><p>Q3 EBITDA</p></td><td></td><td><p>-$2.70 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/LNSR\">LENSAR Inc</a> is $15.00, about 16.5% above its November 5 closing price of $12.52</p></li></ul><p>Press Release: <span>ID:nGNX1j5kbj</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LNSR","symbol_name":"LENSAR Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0LB:1","article_id":"2581346060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581346060","pubTimestamp":1762432136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LENSAR Q3 net loss widensOverviewLENSAR Q3 2025 revenue rises 6% yr/yr, driven by increased procedure volumeNet loss widens to $3.7 mln in Q3, impacted by acquisition-related costsALLY installed base ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LNSR":"LENSAR Inc","BK4082":"医疗保健设备"},"translate_title":"LENSAR第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNSR":0.9},"content_text":"LENSAR Q3 net loss widensOverviewLENSAR Q3 2025 revenue rises 6% yr/yr, driven by increased procedure volumeNet loss widens to $3.7 mln in Q3, impacted by acquisition-related costsALLY installed base grows 77% yr/yr, reflecting strong market adoptionOutlookCompany expects Alcon acquisition to close in Q1 2026Result DriversALLY ADOPTION - Significant growth in ALLY installed base, increasing by 77% yr/yr, driving revenue growthPROCEDURE VOLUME - Worldwide procedure volume increased by 11% in Q3 2025, contributing to revenue growthACQUISITION COSTS - Net loss impacted by $5.3 mln in costs related to pending Alcon acquisitionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$3.70 mlnQ3 EBITDA-$2.70 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy.\"Wall Street's median 12-month price target for LENSAR Inc is $15.00, about 16.5% above its November 5 closing price of $12.52Press Release: ID:nGNX1j5kbjFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581346060","isCrawlerRequest":true}